Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14716412 | 1.00 | KDM4E (0.39) | KDM4EXDHKMT2AMEN1MAPT | |
| SCHEMBL14716707 | 0.83 | TDP1 (0.46) | KDM4EKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL12320826 | 0.82 | MAPT (0.44) | KDM4EXDHKMT2AMEN1MAPT | |
| SCHEMBL14716410 | 0.81 | FGFR1 (0.46) | PNP | |
| SCHEMBL14716576 | 0.71 | ALDH1A1 (0.53) | KDM4EXDHKMT2AMAPTDHFR | |
| SCHEMBL12320442 | 0.71 | ALDH1A1 (0.53) | KDM4EXDHKMT2AMAPTDHFR | |
| SCHEMBL12321218 | 0.69 | TYMS (0.41) | KDM4EKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL12320449 | 0.69 | XDH (0.47) | KDM4EXDHKMT2AMEN1MAPT | |
| SCHEMBL14716709 | 0.69 | TYMS (0.41) | KDM4EKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL14716516 | 0.69 | XDH (0.47) | KDM4EXDHKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458515-B2 | RNA including nucleoside compound, method for regulating amount of protein produced from the RNA, and nucleoside compound | RIKEN (JP) | 2016-10-04 | — | — | US | disclosed |
| US-20130052710-A1 | RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND | RIKEN (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052710-A1 | RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND | RNMT, NSUN2, RNGTT | KDM4E 1577/4885XDH 479/4885KMT2A 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.